Dendritic cells and their role in immunotherapy
Despite significant advances in the field of cancer immunotherapy, the majority of patients
still do not benefit from treatment and must rely on traditional therapies. Dendritic cells have …
still do not benefit from treatment and must rely on traditional therapies. Dendritic cells have …
Antitumour dendritic cell vaccination in a priming and boosting approach
A Harari, M Graciotti, M Bassani-Sternberg… - Nature Reviews Drug …, 2020 - nature.com
Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …
anticancer strategy but has not yet provided robust clinical benefits in large patient …
Wnt signaling pathway in cancer immunotherapy
Wnt/β-catenin signaling is a highly conserved pathway that regulates cell proliferation,
differentiation, apoptosis, stem cell self-renewal, tissue homeostasis, and wound healing …
differentiation, apoptosis, stem cell self-renewal, tissue homeostasis, and wound healing …
[HTML][HTML] Polysaccharides regulate Th1/Th2 balance: a new strategy for tumor immunotherapy
Q Shang, X Yu, Q Sun, H Li, C Sun, L Liu - Biomedicine & Pharmacotherapy, 2024 - Elsevier
T helper (Th) cells have received extensive attention owing to their indispensable roles in
anti-tumor immune responses. Th1 and Th2 cells are two key subsets of Th cells that exist in …
anti-tumor immune responses. Th1 and Th2 cells are two key subsets of Th cells that exist in …
Trial watch: TLR3 agonists in cancer therapy
ABSTRACT Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses
exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in …
exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in …
HER2-positive breast cancer immunotherapy: a focus on vaccine development
A Arab, R Yazdian-Robati, J Behravan - Archivum immunologiae et …, 2020 - Springer
Clinical progress in the field of HER2-positive breast cancer therapy has been dramatically
improved by understanding of the immune regulatory mechanisms of tumor …
improved by understanding of the immune regulatory mechanisms of tumor …
TLR3 agonists: RGC100, ARNAX, and poly-IC: A comparative review
A Komal, M Noreen, AF El-Kott - Immunologic Research, 2021 - Springer
Abstract Toll-like receptors 3 (TLR3) have been broadly studied among all TLRs over the
last few decades together with its agonists due to their contribution to cancer regression …
last few decades together with its agonists due to their contribution to cancer regression …
Targeted therapy and immunotherapy for heterogeneous breast cancer
X Sun, K Liu, S Lu, W He, Z Du - Cancers, 2022 - mdpi.com
Simple Summary Breast cancer (BC) is a common malignancy with molecular diversity, ie,
heterogeneity. Aside from routine clinical treatments, such as chemotherapy and …
heterogeneity. Aside from routine clinical treatments, such as chemotherapy and …
Biomimetic nanoparticles for tumor immunotherapy
H Yu, M Wu, S Chen, M Song, Y Yue - Frontiers in bioengineering …, 2022 - frontiersin.org
Currently, tumor treatment research still focuses on the cancer cells themselves, but the fact
that the immune system plays an important role in inhibiting tumor development cannot be …
that the immune system plays an important role in inhibiting tumor development cannot be …
[HTML][HTML] Immunotherapy in breast cancer: A clinician's perspective
S Chaudhuri, S Thomas, P Munster - Journal of the National Cancer Center, 2021 - Elsevier
Globally over 2 million women are diagnosed with breast cancer each year despite major
advances in detection and treatment of the disease. Breast cancer is comprised of several …
advances in detection and treatment of the disease. Breast cancer is comprised of several …